Viewing nowCombinationTrusita M Tablet 50/500 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.

MFDS item code 202204592 · Approved 2022.12.21 · Insurance code 641908190
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medicine is used in conjunction with diet and exercise therapy to assist patients with type 2 diabetes in controlling their blood sugar levels. Sitagliptin and metformin work together to effectively lower and regulate blood sugar levels, thus serving as a treatment for those who struggle with blood sugar management.
The dose of this drug for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this drug for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be conducted. Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medicine contains sitagliptin and metformin and is used for the treatment of diabetes. First, sitagliptin can rarely cause serious allergic reactions, so if symptoms such as rash or difficulty breathing occur, discontinue use immediately and consult a doctor. Additionally, there have been reports of serious side effects involving pancreatitis, which is inflammation of the pancreas. If you experience symptoms such as abdominal pain, vomiting, or loss of appetite, inform your healthcare provider immediately. The metformin component can rarely induce a dangerous state known as lactic acidosis, which is due to the accumulation of acidic substances in the body, exhibiting symptoms such as muscle pain, weakness, difficulty breathing, and abdominal pain. This medicine should not be administered to patients with moderate to severe renal dysfunction, severe infections, heart failure, or acute myocardial infarction. It must also be discontinued before and after examinations using iodinated contrast agents. Its safety in pregnant or breastfeeding women, and in patients under 18 years old, has not been established, and it is advisable not to use this medication in these populations. While taking this medicine, it is essential to maintain a regular diet and adequate exercise, as well as to regularly check blood sugar levels and kidney function. Also, hypoglycemia may occur, and therefore you should take care to quickly address it by consuming sugar. Be cautious, as there may be an increased risk of hypoglycemia when used in conjunction with other hypoglycemic agents or alcohol. In situations such as surgery or severe infections, this medication should be temporarily discontinued, and should be restarted only after the condition stabilizes. If severe joint pain, skin rash, or blistering disease occurs during treatment, inform your doctor immediately and seek treatment. Finally, there may be interactions with other medications being taken along with this medicine, so it is important to inform your healthcare provider of any other drugs you are currently using.
Not everyone experiences these, and they can vary from person to person.
Store this medicine in an airtight container and at a temperature between 1 to 30 degrees Celsius (room temperature). This can help maintain the effectiveness of the medication and prevent deterioration.
Bright pink oval film-coated tablet
30 tablets/bottle, 200 tablets/bottle, 56 tablets/box [(14 tablets/PTPx4)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.